Maia Biotechnology, Inc. · AMEX:MAIA
Maia Biotechnology — Investor Presentation (October 2026)
28 slides from Maia Biotechnology's investor presentation, Oct 6, 2026
Slide 1: MAIA Biotechnology: Telomere Targeting Immunotherapies for Cancer
MAIA BIOTECHNOLOGY TELOMERE TARGETING IMMUNOTHERAPIES FOR CANCER NYSE AMERICAN: MAIA Fall 2026
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS MAIA NYSE American: MAIA All statements in this presentation, other than those relating to historical facts, are "forward-looking statements." These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans, and strategies
Slide 3: MAIA Biotech Investment Profile
MAIA BIOTECH INVESTMENT PROFILE for I ii mec of Ateganosine (THIO): lead molecule in 2 ongoing clinical trials Second generation compounds in R&D QO Phase 3 Trial (ongoing): THIO-104 QO Phase 2 trial (ongoing): THIO-101 * Ateganosine + Libtayo® vs. Investigator’s Choice in Non- * Ateganosine + Libta
Slide 4: Achievements to Date
ACHIEVEMENTS TO DATE Regulatory achievements to date Multiple Ateganosine (THIO) + * 3U.S. FDA Orphan Drug Designations: checkpoint inhibitor trials planned * Hepatocellular Carcinoma (HCC, 90% of primary liver for additional cancer indications cancers) ¢ BeOne Medicines: clinical supply agreement f
Slide 5: Pipeline
PIPELINE Clinical Trials with Ateganosine 7 . — Worldwide rights Clinical Trial Indication Treatment Status owned by MAIA THIO-104 NSCLC-3 Ateganosine > Libtayo® F THIO-101 NSCLC-3 Ateganosine > Libtayo® Ongoing Phase 2 rae THIO-CRC CRC-3 Ateganosine > tislelizumab Planned Phase 2* a Clinical supply
Slide 6: Mechanism of Action
MECHANISM OF ACTION €9 Telomere-Targeting . Ateganosine is a guanine analog incorporated into telomeres by telomerase, active in >80% of cancers. This disrupts telomere structure and function, triggering selective cancer cell death.’ Immunogenic Effect Ateganosine-modified telomeric DNA fragments fo
Slide 7: Curative Preclinical Studies
CURATIVE PRECLINICAL STUDIES In models, Ateganosine followed by CPI results in 60% complete response (CR) Only 2 cycles of therapy were administered on weeks 1 and 2; no further therapy throughout the study No recurrence after long-term follow-up. 70 days in mice models are comparable to 7 years in
Slide 8: Potential for Partnerships
POTENTIAL FOR PARTNERSHIPS Ateganosine followed by a CPI has the potential to change the treatment landscape of multiple tumor types Great potential for expansion * Studies with Ateganosine with multiple CPls in other cancer models (including liver, colorectal, brain and more) have been conducted wi
Slide 9: NSCLC Clinical Trials
NSCLC CLINICAL TRIALS
Slide 10: Phase 2 Trial Ongoing (THIO-101)
PHASE 2 TRIAL ONGOING NYSE American: MAIA THIO-101: A Multicenter, Open-label, Dose-Finding Phase 2 Trial Evaluating the Safety and Efficacy of Ateganosine (THIO) Administered in Sequence with Libtayo® (cemiplimab) in NSCLC Patients Who Are Resistant to Checkpoint Inhibitors Parts A & B (Completed)
Slide 11: Observed outcomes from THIO-101 (Parts A and B)
Observed outcomes from THIO-101 (Parts A and B): THIO-101 Chemo (RWD) mOS 17.8 months (3L) ~5.8 months? DCR 88% (3L 180mg) ~25-35%12 ORR 38% (3L 180mg) ~6-10%1 art C completed enrollment in July 2026 * Ongoing efficacy evaluation, 88% DCR confirmed in Part C ¢ As of July 2026, two patients have surp
Slide 12: Phase 3 Trial Designed for Highest Potential
PHASE 3 TRIAL DESIGNED FOR HIGHEST POTENTIAL THIO-104: A Multicenter, Open-label, Pivotal Phase 3 Trial Evaluating the Efficacy of Ateganosine (THIO) Administered in Sequence with Libtayo® (cemiplimab) in NSCLC Patients Who Are Resistant to Checkpoint Inhibitors and Chemotherapy @ >) | | Patient Pop
Slide 13: High Probability of Technical Success
HIGH PROBABILITY OF TECHNICAL SUCCESS wee OS is the primary endpoint 90% power to detect HR=0.62, median 9.4 months vs 5.8 months! (chemo) Interim analysis boundary 1-sided p<0.0074 at 131 deaths Final analysis boundary 1-sided p<0.0228 at 186 deaths THIO-104 Design Bayesian Assurance? Calculation 9
Slide 14: Market Entry Strategy - Summary
MARKET ENTRY STRATEGY - SUMMARY 3L NSCLC is an excellent market entry segment: Highly unmet medical need Q. The immunotherapy-resistant and chemotherapy-resistant population desperately need other options Pp No standard of care (2) Lack of established treatment and guidelines for patients 3 Large pa
Slide 15: Planned Trials in Other Tumor Types
PLANNED TRIALS IN OTHER TUMOR TYPES
Slide 16: Complete Responses Observed in CRC
COMPLETE RESPONSES OBSERVED IN CRC Preclinical Studies in Colorectal Cancer | = 70° =e-Contiol € 600 —e—Atezolizumab £ —e—Ateganosine followed by CPI A 500 —e—Ateganosine > Atezo results in 100% complete response 5 400 S$ 300 S E 200 100% CR Only 2 cycles of therapy were e 100 administered on weeks
Slide 17: Vast Number of Studies in Liver
VAST NUMBER OF STUDIES IN LIVER Preclinical Studies in Hepatocellular Carcinoma Ateganosine (THIO) achieved complete and G durable responses in Hepatocellular Carcinoma 1500 HCC (HCC), the dominant histology in primary liver —e—Control cancer (90%) 1250 —e—Ateganosine —e—Ateganosine > IR —e-—IR + At
Slide 18: HCC Anti-Cancer Immune Memory
HCC ANTI-CANCER IMMUNE MEMORY Sustained Anti-Tumor Response en 2000 Ee E 1500) 5x108cell ° When combined with e injected . immunotherapy checkpoint 3 1000 inhibitor Libtayo®, duration of 5 500 response was further potentiated 2 © Control -e- Ateganosine -@ Libtayo ~e- Ateganosine+Libtayo ; li 24-0 a
Slide 19: Great Potential in Small Cell Lung Cancer
GREAT POTEN Preclinical Studies in Small Cell Lung Cancer Ateganosine (THIO) is synergistic with anti-PD-1 agent Pembrolizumab in Small Cell Lung re Carcinoma (SCLC) in vivo in humanized murine cancer model (H2081) Treatment with Ateganosine followed by Pembrolizumab results in highly potent antican
Slide 20: Multiple Trials Planned in Other Cancers
IPLE TRIALS PLANNED IN OTHER CANCERS Multicenter, Open-label, Phase 2 Trials Evaluating the Safety and Efficacy of Ateganosine (THIO) Administered in Sequence with Tislelizumab in CRC, SCLC and HCC | Part A/B: Safety/Efficacy Signal (n=~40) | ee Colorectal Cancer (CRC) Ateganosine Immune Activation
Slide 21: Investment Opportunity
INVESTMENT OPPORTUNITY
Slide 22: Experienced Management Team
EXPERIENCED MANAGEMENT TEAM Founder and CEO * 25+ years in Oncology Pharma/ Biotech: Commercial, Medical * 12 compounds launched across 20+ tumor types + Leadership roles at * Bayer (Nexavar), ¢ Astellas (Tarceva, Xtandi), * Cephalon (Treanda), * Novartis (Zometa), Incyte (Jakafi) Decades of Experie
Slide 23: Intellectual Property
L PROPERTY al: New Chemical Entity (NCE) Marketing Exclusivity Robust and Growing Patent Portfolio for THIO iali i issued patents Europe Pending Patent commercialization Validated in 19 countries Applications Robust exclusivity Current patents/provisional applications broadly cover * US: Upon FDA ap
Slide 24: NSCLC is only the beginning
NSCLC is only the beginning. MAIA is developing therapies for the top tumor types markets globally. ? NSCLC (#1 worldwide) CRC (#2 worldwide) Mortality: 1.7M Mortality: 1.0M Sales: $34B Sales: $20B Hec SCLC Mortality: 0.8M Mortality: 0.3M Sales: $3.8B Sales: $2.8B NSCLC market is expanding to $70B.
Slide 25: Thank You
THANK YOU a la. Investor Relations Contact ~— —= +1 (872) 270-3518 eo. a —_ ir@maiabiotech.com @ MAIA Biotechnology, Inc. Pea 444 West Lake Street, Suite 1700 — Chicago, IL 60606 —
Slide 26: Appendix
APPENDIX
Slide 27: THIO-101 - Baseline Characteristics
THIO-101 - BASELINE C At the time of cutoff June 30, 2025, 79 subjects with advanced NSCLC received at least one dose of the study drug All subjects had previously failed at least 1 prior line of ICI +/- chemotherapy in the advanced setting and had documented disease progression at study entry 34% o
Slide 28: THIO-101 - Safety Summary (Parts A & B)
THIO-101 - SAFETY SUMMARY (PARTS A & B) * Overall, as of the cut-off date 15Jan2025, THIO + cemiplimab been generally well tolerated in a heavily pre- treated population, with most events being Grade 1-2 in severity. * Most Treatment Emergent Adverse Events (TEAEs) were laboratory value elevations,
MAIA Biotechnology — Investor Presentation (October 2026) on 6ix